L'essentiel sur "Autisme et Inclusion"

Help us | Aidez-nous

Sat Jan 22 16:30:02 CET 2022 France - It's time to Stand Up! For inclusion
19/01/22 FDA cites hair-based autism diagnostic aid as ...˜breakthrough' | Spectrum | Autism Research News [spectrumnews]
12/01/22 Observations finales concernant le rapport initial de la France* CRPD/C/FRA/CO/1 - G2126973.pdf [documents-dds-ny.un]
29/12/21 Oxytocin in a developing fish brain determines later social behavior [medicalxpress]
22/12/21 Arrete du 22 decembre 2021 modifiant l'arrete du 28 novembre 2019 relatif a l'experimentation pour un parcours de soins coordonne des enfants et adolescents proteges - Legifrance [legifrance.gouv]
25/11/21 Researchers develop compound for autism treatment | Bengaluru News - Times of India [timesofindia.indiatimes]
07/11/21 Pass sanitaire : la liste des contre-indications medicales s'elargit - Faire Face - Toute l'actualite du handicap [faire-face]
03/11/21 Complex PTSD in young people in care - ACAMH [acamh]

FDA cites hair-based autism diagnostic aid as ...˜breakthrough' | Spectrum | Autism Research News 19/01/2022

«The U.S. Food and Drug Administration (FDA) has granted ...˜breakthrough device' designation to a hair-based test designed to aid autism diagnosis. The acknowledgment shifts the test into a fast lane through the agency's regulatory review process. The test, called StrandDx, analyzes the levels of chemicals in a strand of a child's hair to capture a snapshot of her ...˜exposome' ...” some of her cumulative environmental exposures and how she regulates certain essential nutrients. The measures suggest how a person's physiology responds to her environment, which can predict her chances of having autism, says Manish Arora, Edith J. Baerwald Professor and vice chairman of environmental medicine and public health at the Icahn School of Medicine at Mount Sinai in New York City and co-founder of New York-based Linus Biotechnology, which is developing the test.»...

<< Sommaire
spectrumnews

Observations finales concernant le rapport initial de la France* CRPD/C/FRA/CO/1 - G2126973.pdf 12/01/2022


«» [...]
« I. Introduction 1. Le Comité a examiné le rapport initial de la France1 à ses 539e, 540e et 541e séances, tenues en ligne les 18, 20 et 23 août 20212. Il a adopté les observations finales ci-après à sa 549e séance, tenue en ligne le 7 septembre 2021. 2. Le Comité accueille avec satisfaction le rapport initial de la France, qui a été établi conformément aux directives concernant l’établissement des rapports, et remercie l’État partie des réponses écrites3 apportées à la liste de points4. 3. Le Comité remercie l’État partie d’avoir accepté que l’examen de son rapport initial se déroule entièrement en ligne, compte tenu des circonstances exceptionnelles dues à la pandémie de maladie à coronavirus (COVID-19). Il se félicite du dialogue sincère et fructueux qu’il a eu avec la délégation, à la composition diversifiée et multisectorielle et dans laquelle les ministères compétents étaient représentés. Il se félicite également de la participation du Défenseur des droits, en sa qualité de mécanisme indépendant de suivi au titre de l’article 33 (par. 2) de la Convention, et de la Commission nationale consultative des droits de l’homme, en sa qualité d’institution nationale des droits de l’homme de l’État partie. »...

<< Sommaire
documents-dds-ny.un

Oxytocin in a developing fish brain determines later social behavior 29/12/2021

«Whenever we decide to throw a party, invite in-laws to dinner or embark on a cruise, we are driven by the most basic component of social behavior: The desire to hang out with other humans. Considering that the drive to form groups with members of one's own species has been conserved throughout evolution, it's evident that social behavior is governed by genes, at least to some degree. But our parents and teachers help us hone our social graces, so teasing apart the effects of nature and nurture on this behavior is hard, if not impossible. By studying zebrafish, Weizmann Institute of Science researchers, in collaboration with scientists in Portugal, have managed to solve part of the riddle of how social behavior is hardwired into the developing brain.»
[...]
« At about four weeks of age, the centimeter-long juvenile fish, just out of the larval stage, begin to socialize. Though not as exquisitely synchronized as the schools of moonfish in "Finding Nemo," they do exhibit a strong tendency to swim together as a group, termed a shoal. Much like humans, they have an incentive to seek company; in their case, the group provides them with advantages in searching for food, overcoming currents, avoiding predators and finding mates. The shoaling behavior of zebrafish requires sophisticated processing of visual and social cues, very similar to that which takes place in the brains of socializing humans. In particular, the zebrafish must be able to identify other fish as belonging to their own, "friendly"—as opposed to different or, worse yet, predatory—species. To learn how the social behavior of zebrafish develops, the researchers decided to focus on the hormone oxytocin, one of the most important neurochemicals known to enhance social interactions, including bonding. Postdoctoral fellow Dr. Ana Rita Nunes and doctoral student Michael Gliksberg created a system for exploring the effects of oxytocin on the developing brains of zebrafish larvae. They produced transgenic larvae whose oxytocin-making neurons harbored a bacterial gene encoding fatal sensitivity to antibiotics. The researchers could then eliminate these neurons from the brains of the larvae at different stages of their development by adding antibiotics to the water, and they later observed the zebrafish behavior as they became adults. »...

<< Sommaire
medicalxpress

Arrete du 22 decembre 2021 modifiant l'arrete du 28 novembre 2019 relatif a l'experimentation pour un parcours de soins coordonne des enfants et adolescents proteges - Legifrance 22/12/2021

«Article 1 Le cahier des charges modifié susvisé de l'expérimentation pour un parcours de soins coordonné des enfants et adolescents protégés annexé au présent arrêté remplace le cahier des charges annexé à l'arrêté du 28 novembre 2019. Article 2 Le directeur de la sécurité sociale et la directrice générale de la cohésion sociale sont chargés, chacun en ce qui le concerne, de l'exécution du présent arrêté, qui sera publié, ainsi que ses annexes, au Journal officiel de la République française. ReplierAnnexe Article ANNEXE I CAHIER DES CHARGES RELATIF A L'EXPERIMENTATION Parcours de soins coordonné des enfants et adolescents protégés : Projet d'expérimentation dans le cadre de l'article 51 de la FLSS 2018 Projet national porté par la DGCS et le docteur Nathalie Vabres (CHU de Nantes) Objet et finalité du projet d'expérimentation / enjeu de l'expérimentation 1. Eléments de diagnostic»...

<< Sommaire
legifrance.gouv

Researchers develop compound for autism treatment | Bengaluru News - Times of India 25/11/2021

«Bengaluru: A group of researchers from Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) in Bengaluru has developed a compound called 6BIO that can provide a better method to treat Autism Spectrum Disorder (ASD). The team has already determined the potency of the compound in a preclinical mice model. It says this is the first compound that has been proved in preclinical evaluation to have the potential for improving efficiency of daily activities like learning and recollecting new tasks in patients with ASD/intellectual disability (ID).The research ...” carried out by Vijaya Verma, MJ Vijay Kumar, Kavita Sharma, Sridhar Rajaram, Ravi Muddashetty, Ravi Manjithaya, Thomas Behnisch and James P Clement from JNCASR ...” has been published in Experimental Brain Research.»
[...]
« "Previous studies have attributed disruption in optimal brain development, mainly neuronal connections, during the early stage of development (babies/childhood) as one of the causes of ASD/ID. Due to altered brain development, information processing becomes aberrant and understanding simple tasks becomes exceptionally challenging for patients with ASD/ID," the researchers said.Pointing out that current therapeutics to treat ASD aim to alleviate symptoms such as epileptic seizures or sleep issues but not to treat the multiple problems of ASD/ID, they said a major challenge in finding better therapeutics is the potency of the drug to help patients perform daily activities with efficiency close to that of a healthy person. Achieving this is particularly difficult after a certain age, especially from the mid-childhood stages, they said, adding that ASD patients still struggle to perform everyday activities without assistance from others as they are unable to learn and recollect new tasks. "Data from the current study indicates that 6BIO ...” synthesised in JNCASR ...” can help such children learn and recall, be social, and alleviate other symptoms such as seizures or sleep issues. Thus, 6BIO, can be a better therapeutics option to treat ASD," they said. Using electrophysiology, which helps understand how neurons communicate, and behaviour experiments, which indicate the overall brain function, the team has shown that 6BIO can restore the information processing in the preclinical mouse model. Therefore, the compound, they said, had a strong potential for therapeutics to treat ASD/ID. ...˜Restored neural functions after mid-childhood too'All the behaviour and electrophysiology work was performed in Dr James Clement's lab at JNCASR, the authors said, adding that another novelty of this study was that 6BIO restored the neural functions not only when administered during development (1-2 years) and childhood stages (3-6 years) but also after mid-childhood (7-11 years) when most of the brain regions are considered to have formed properly. »...

<< Sommaire
timesofindia.indiatimes

Pass sanitaire : la liste des contre-indications medicales s'elargit - Faire Face - Toute l'actualite du handicap 07/11/2021

«Le Gouvernement vient de reconnaitre une nouvelle catégorie de contre-indications médicales à la vaccination anti-Covid-19. Elle concerne les patients atteints de maladies rares pour lesquels les experts de ces pathologies déconseillent le vaccin. C'est le cas notamment de la fibrodysplasie ossifiante progressive. Un récent décret vient d’élargir la – très courte – liste initiale qui avait été instituée le 7 août.»
[...]
«Une nouvelle catégorie de contre-indications Un récent décret vient d’élargir la – très courte – liste initiale qui avait été instituée le 7 août. « Une recommandation établie par un centre de référence maladies rares (CRMR) ou un centre de compétence maladies rares (CCMR) après concertation médicale pluridisciplinaire (avis collégial) de ne pas initier la vaccination contre la Covid-19 » permet désormais également d’obtenir un certificat faisant office de pass sanitaire. Cette nouvelle catégorie de contre-indications ne pointe donc pas nommément la Fop ou une autre maladie mais renvoie à l’appréciation par les experts de ces pathologies rares. !3_________ Quelles sont les contre-indications médicales reconnues aux vaccins anti-Covid-19 ? Le décret du 7 août modifié par le décret du 29 août dresse une liste de contre-indications ouvrant droit à un certificat médical faisant office de pass sanitaire : – allergie à un des composants du vaccin ; – réaction anaphylactique au moins de grade 2 à une première injection d’un vaccin contre le Covid ; – personnes ayant déjà présenté des épisodes de syndrome de fuite capillaire (contre-indication commune au vaccin Vaxzevria et au vaccin Janssen) ; – syndrome inflammatoire multi-systémique pédiatrique (Pims) post-Covid-19 ; – une recommandation établie après concertation médicale pluridisciplinaire de ne pas effectuer la seconde dose de vaccin suite à la survenue d’un effet indésirable d’intensité sévère ou grave (myocardite, syndrome de Guillain-Barré…). Il précise aussi deux contre-indications temporaires : – traitement par anticorps monoclonaux anti-SARS-CoV-2 ; – myocardites ou péricardites d’étiologie non liée à une infection par SARS-CoV-2 survenues antérieurement à la vaccination et toujours évolutives. »...

<< Sommaire
faire-face

Complex PTSD in young people in care - ACAMH 03/11/2021

«In March 2021 we joined CAMHS around the Campfire, the online journal club run by ACAMH with the Mental Elf, to discuss Rachel's recent paper on complex posttraumatic stress disorder (PTSD) in young people in care.1 Briefly, this paper presented results of a longitudinal study exploring the role of key cognitive predictors of both ...˜standard' PTSD and complex PTSD symptoms. The sample included 120 10-18 year-olds living in care in England. The study found that our current models of PTSD were applicable to young people in care. Maladaptive cognitions (e.g., "I can't trust anyone" or "the world isn't safe"), cognitive coping (e.g., avoiding thinking about what happened), and memory qualities (e.g., memories being muddled or confused) were all associated with PTSD symptoms and complex features. Maladaptive cognitions were particularly important. This suggests that targeting these mechanisms in intervention would be useful for young people with complex PTSD symptoms. In this article we reflect on some of the important points raised in the Campfire discussion about this research.»
[...]
«Are PTSD and complex PTSD different? PTSD is a trauma-specific mental health difficulty. A young person who has experienced trauma (whether that might be called maltreatment, complex trauma, developmental trauma, or any other trauma exposure) is at risk of developing PTSD. According to the World Health Organisation’s diagnostic classification system (ICD-11), PTSD includes three symptom clusters: re-experiencing the trauma, avoiding reminders of the trauma and hyper-arousal. Young people with PTSD commonly also have other mental health problems, such as depression or anxiety. We know that rates of PTSD are very high in care-experienced young people. Complex PTSD is a new diagnosis in the ICD-11, but has not been included in the American Psychiatric Association’s diagnostic classification system (DSM-5). Crucially, to meet criteria for complex PTSD, the young person must have PTSD as well as additional complex features of difficulties with: relationships, emotion dysregulation and negative self-concept (e.g., “I’m not worth anything”). Rachel’s work indicates that the same processes that drive PTSD, also drive complex PTSD. This suggests we may not need to develop completely new treatments for complex PTSD. We already have interventions that target these processes – called trauma-focused cognitive behaviour therapies (tf-CBT), the NICE-recommended first-line treatment for PTSD.2 There is growing research supporting this by showing that tf-CBT is an effective treatment for those with complex presentations.3 It’s possible that young people with complex presentations may benefit from more sessions to allow a more in-depth focus on certain aspects of treatment. Getting young people in care the right treatment It’s important that young people in care get the right treatment to address their needs. We know that even our best evidenced treatments do not work 100% of the time for 100% of young people, but they should be the starting point to giving young people the best chance at overcoming their mental health difficulty. As with any treatment, it is also important that the young person receives appropriate psychoeducation, not just about PTSD, but also about the treatment. People with PTSD often want to avoid thinking about what they have been through, which means they might struggle to engage in earlier sessions or not turn up to some sessions. In the psychoeducation component of tf-CBT it is important that avoidance is openly discussed. Similarly, it can be useful for practitioners to reflect on whether they may inadvertently encourage avoidance by delaying starting parts of treatment that are harder, such as memory work. We also acknowledge the barriers that often exist in services that might mean practitioners find it difficult to deliver tf-CBT. It might be that they are not able to provide the required 12-20 sessions, or that they do not have training and supervision available to them. But there also seems to be a pervasive belief that tf-CBT is not appropriate for young people exposed to complex trauma, like abuse. This belief is not supported by the evidence or the most recent NICE review for PTSD, and is also challenged by mechanism research. Understanding how we can address service-level and individual-level barriers remains an important area of research, so practitioners and services can be encouraged and supported to deliver evidence-based treatments, such as tf-CBT. Listening to young people in care »...

<< Sommaire
acamh